1. Monitoring Milestones in Patients With Chronic Myeloid Leukemia

2. Activity Goal

3. Treatment Milestones

4. Workup: Patient Newly Diagnosed in Chronic Phase

5. Definition of Response in CML

6. Definition of Response in CML (cont)

7. Response Milestones: Frontline Imatinib in Chronic Phase CML

8. Faster Responses With Nilotinib and Dasatinib

9. Prediction of Outcome Based on the 3-month Time Point

10. BCR-ABL/ABL < 10% by IS at 3 Months Predicts Outcome

11. What Are the Options When the 3-month Time Point Has NOT Been Reached?

12. At 3 Months, BCR-ABL of ≥ 10% IS Identifies High-Risk Patients

13. Retrospective Analysis of CML Study IV MMR and CCyR at 3 Months

14. Considerations for the 3-month Time Point

15. Conclusions

16. Monitoring at the 6-Month Time Point

17. Monitoring at the 6-month Time Point

18. Rise and Fall of BCR-ABL Transcript Levels With Imatinib Dosing

19. Retrospective Analysis of CML Study IV MMR and CCyR at 6 Months

20. Monitoring at the 12-Month Time Point

21. 12-month Follow-up

22. 12-month Follow-up (cont)

23. 12-month Follow-up (cont)

24. 12-month Follow-up: Relapse

25. Algorithm for Modulating Risk Factors

26. BCR-ABL KD Mutations Before and After Imatinib Therapy

27. Conclusions

28. Monitoring Patients at the 18-Month Time Point

29. Monitoring at the 18-month Time Point

30. Event-free Survival by Response

31. Monitoring at the 18-month Time Point

32. Treating Patients With Mutations in the Second Linea,b

33. Results With Second-/Third-Generation TKI After Imatinib Failure/Resistance

34. Cytogenetic Relapse at 18 months

35. Best Molecular Response

36. Thank you for participating in this activity.